FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2124451268> ?p ?o ?g. }

• W2124451268 endingPage "653" @default.
• W2124451268 startingPage "642" @default.
• W2124451268 abstract "When cure is impossible, cancer treatment should focus on both length and quality of life. Maximisation of time without toxic effects could be one effective strategy to achieve both of these goals. The COIN trial assessed preplanned treatment holidays in advanced colorectal cancer to achieve this aim.COIN was a randomised controlled trial in patients with previously untreated advanced colorectal cancer. Patients received either continuous oxaliplatin and fluoropyrimidine combination (arm A), continuous chemotherapy plus cetuximab (arm B), or intermittent (arm C) chemotherapy. In arms A and B, treatment continued until development of progressive disease, cumulative toxic effects, or the patient chose to stop. In arm C, patients who had not progressed at their 12-week scan started a chemotherapy-free interval until evidence of disease progression, when the same treatment was restarted. Randomisation was done centrally (via telephone) by the MRC Clinical Trials Unit using minimisation. Treatment allocation was not masked. The comparison of arms A and B is described in a companion paper. Here, we compare arms A and C, with the primary objective of establishing whether overall survival on intermittent therapy was non-inferior to that on continuous therapy, with a predefined non-inferiority boundary of 1.162. Intention-to-treat (ITT) and per-protocol analyses were done. This trial is registered, ISRCTN27286448.1630 patients were randomly assigned to treatment groups (815 to continuous and 815 to intermittent therapy). Median survival in the ITT population (n=815 in both groups) was 15.8 months (IQR 9.4-26.1) in arm A and 14.4 months (8.0-24.7) in arm C (hazard ratio [HR] 1.084, 80% CI 1.008-1.165). In the per-protocol population (arm A, n=467; arm C, n=511), median survival was 19.6 months (13.0-28.1) in arm A and 18.0 months (12.1-29.3) in arm C (HR 1.087, 0.986-1.198). The upper limits of CIs for HRs in both analyses were greater than the predefined non-inferiority boundary. Preplanned subgroup analyses in the per-protocol population showed that a raised baseline platelet count, defined as 400,000 per μL or higher (271 [28%] of 978 patients), was associated with poor survival with intermittent chemotherapy: the HR for comparison of arm C and arm A in patients with a normal platelet count was 0.96 (95% CI 0.80-1.15, p=0.66), versus 1.54 (1.17-2.03, p=0.0018) in patients with a raised platelet count (p=0.0027 for interaction). In the per-protocol population, more patients on continuous than on intermittent treatment had grade 3 or worse haematological toxic effects (72 [15%] vs 60 [12%]), whereas nausea and vomiting were more common on intermittent treatment (11 [2%] vs 43 [8%]). Grade 3 or worse peripheral neuropathy (126 [27%] vs 25 [5%]) and hand-foot syndrome (21 [4%] vs 15 [3%]) were more frequent on continuous than on intermittent treatment.Although this trial did not show non-inferiority of intermittent compared with continuous chemotherapy for advanced colorectal cancer in terms of overall survival, chemotherapy-free intervals remain a treatment option for some patients with advanced colorectal cancer, offering reduced time on chemotherapy, reduced cumulative toxic effects, and improved quality of life. Subgroup analyses suggest that patients with normal baseline platelet counts could gain the benefits of intermittent chemotherapy without detriment in survival, whereas those with raised baseline platelet counts have impaired survival and quality of life with intermittent chemotherapy and should not receive a treatment break.Cancer Research UK." @default.
• W2124451268 created "2016-06-24" @default.
• W2124451268 creator A5008462756 @default.
• W2124451268 creator A5010914696 @default.
• W2124451268 creator A5017956085 @default.
• W2124451268 creator A5026585062 @default.
• W2124451268 creator A5027160662 @default.
• W2124451268 creator A5029188434 @default.
• W2124451268 creator A5029890517 @default.
• W2124451268 creator A5036848123 @default.
• W2124451268 creator A5037391345 @default.
• W2124451268 creator A5040991512 @default.
• W2124451268 creator A5042615950 @default.
• W2124451268 creator A5050254542 @default.
• W2124451268 creator A5053919588 @default.
• W2124451268 creator A5058223039 @default.
• W2124451268 creator A5058562981 @default.
• W2124451268 creator A5063738443 @default.
• W2124451268 creator A5072980689 @default.
• W2124451268 creator A5073739923 @default.
• W2124451268 creator A5084664193 @default.
• W2124451268 creator A5088213146 @default.
• W2124451268 date "2011-07-01" @default.
• W2124451268 modified "2023-10-14" @default.
• W2124451268 title "Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial" @default.
• W2124451268 cites W1674079630 @default.
• W2124451268 cites W1985042100 @default.
• W2124451268 cites W2008778169 @default.
• W2124451268 cites W2016293379 @default.
• W2124451268 cites W2049750642 @default.
• W2124451268 cites W2102601598 @default.
• W2124451268 cites W2106475544 @default.
• W2124451268 cites W2109498035 @default.
• W2124451268 cites W2118971132 @default.
• W2124451268 cites W2124440635 @default.
• W2124451268 cites W2131098741 @default.
• W2124451268 cites W2139248078 @default.
• W2124451268 cites W2144690940 @default.
• W2124451268 cites W2145070131 @default.
• W2124451268 cites W2146161922 @default.
• W2124451268 cites W2155844247 @default.
• W2124451268 doi "https://doi.org/10.1016/s1470-2045(11)70102-4" @default.
• W2124451268 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3159416" @default.
• W2124451268 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21641867" @default.
• W2124451268 hasPublicationYear "2011" @default.
• W2124451268 type Work @default.
• W2124451268 sameAs 2124451268 @default.
• W2124451268 citedByCount "226" @default.
• W2124451268 countsByYear W21244512682012 @default.
• W2124451268 countsByYear W21244512682013 @default.
• W2124451268 countsByYear W21244512682014 @default.
• W2124451268 countsByYear W21244512682015 @default.
• W2124451268 countsByYear W21244512682016 @default.
• W2124451268 countsByYear W21244512682017 @default.
• W2124451268 countsByYear W21244512682018 @default.
• W2124451268 countsByYear W21244512682019 @default.
• W2124451268 countsByYear W21244512682020 @default.
• W2124451268 countsByYear W21244512682021 @default.
• W2124451268 countsByYear W21244512682022 @default.
• W2124451268 countsByYear W21244512682023 @default.
• W2124451268 crossrefType "journal-article" @default.
• W2124451268 hasAuthorship W2124451268A5008462756 @default.
• W2124451268 hasAuthorship W2124451268A5010914696 @default.
• W2124451268 hasAuthorship W2124451268A5017956085 @default.
• W2124451268 hasAuthorship W2124451268A5026585062 @default.
• W2124451268 hasAuthorship W2124451268A5027160662 @default.
• W2124451268 hasAuthorship W2124451268A5029188434 @default.
• W2124451268 hasAuthorship W2124451268A5029890517 @default.
• W2124451268 hasAuthorship W2124451268A5036848123 @default.
• W2124451268 hasAuthorship W2124451268A5037391345 @default.
• W2124451268 hasAuthorship W2124451268A5040991512 @default.
• W2124451268 hasAuthorship W2124451268A5042615950 @default.
• W2124451268 hasAuthorship W2124451268A5050254542 @default.
• W2124451268 hasAuthorship W2124451268A5053919588 @default.
• W2124451268 hasAuthorship W2124451268A5058223039 @default.
• W2124451268 hasAuthorship W2124451268A5058562981 @default.
• W2124451268 hasAuthorship W2124451268A5063738443 @default.
• W2124451268 hasAuthorship W2124451268A5072980689 @default.
• W2124451268 hasAuthorship W2124451268A5073739923 @default.
• W2124451268 hasAuthorship W2124451268A5084664193 @default.
• W2124451268 hasAuthorship W2124451268A5088213146 @default.
• W2124451268 hasBestOaLocation W21244512681 @default.
• W2124451268 hasConcept C121608353 @default.
• W2124451268 hasConcept C126322002 @default.
• W2124451268 hasConcept C141071460 @default.
• W2124451268 hasConcept C143998085 @default.
• W2124451268 hasConcept C168563851 @default.
• W2124451268 hasConcept C2776694085 @default.
• W2124451268 hasConcept C2780962732 @default.
• W2124451268 hasConcept C2908647359 @default.
• W2124451268 hasConcept C526805850 @default.
• W2124451268 hasConcept C71924100 @default.
• W2124451268 hasConcept C99454951 @default.
• W2124451268 hasConceptScore W2124451268C121608353 @default.
• W2124451268 hasConceptScore W2124451268C126322002 @default.
• W2124451268 hasConceptScore W2124451268C141071460 @default.
• W2124451268 hasConceptScore W2124451268C143998085 @default.
• W2124451268 hasConceptScore W2124451268C168563851 @default.

• next